EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 289 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride /... June 28, 2024 Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination... December 9, 2020 FDA Proposes Changes to Mammography Standards to Inform Women About Breast... March 28, 2019 Teenage (…and young adult) kicks April 5, 2023 Load more HOT NEWS EMA Recommends Extension of Indications for Daratumumab Can Having Solar Panels or Living Near a Solar Farm Increase... With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era Association of BRCA1 and BRCA2 Pathogenic Variants with Increased Risk of...
